DNLI insider transaction filings
Denali Therapeutics Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-09. Screen DNLI transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 4 filings by 3 insiders — 18,718 shares, $435,303 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
- Largest priced transaction: sale of 10,824 shares @ $22.85 ($247,328) by Thornberry Nancy, filed 2026-09-04.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Thornberry Nancy — Director | 1 | — | 2 legs · 11,439 sh · $261,929 | — |
| Schuth Alexander O. — COFO and Secretary | 2 | — | 2 legs · 5,625 sh · $136,507 | — |
| Chin Peter Scott — Chief Medical Officer | 1 | — | 1 leg · 1,654 sh · $36,868 | — |
| Watts Ryan J. — President and CEO, Director | 1 | — | — | 1 |
Recent Form 4 filings — Denali Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Chin Peter Scott — Chief Medical Officer | Sale (S): 1,654 @ $22.29 | EDGAR |
| 2026-09-04 | 4 | Thornberry Nancy — Director | Sale (S): 10,824 @ $22.85 · Sale (S): 615 @ $23.74 | EDGAR |
| 2026-09-03 | 4 | Schuth Alexander O. — COFO and Secretary | Sale (S): 2,768 @ $23.44 | EDGAR |
| 2026-08-14 | 4 | Watts Ryan J. — President and CEO, Director | Gift (G): 32,220 @ $0 | EDGAR |
| 2026-08-13 | 4 | Schuth Alexander O. — COFO and Secretary | Sale (S): 2,857 @ $25.07 | EDGAR |
| 2026-06-05 | 4 | Van Hauwermeiren Timothy — Director | Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Thornberry Nancy — Director | Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Cook Jennifer E. — Director | Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Krognes Steve E. — Director | Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Schenkein David P — Director | Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Klein Peter S — Director | Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | FLATLEY JAY T — Director | Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 6,408 @ $0 · Grant/award (A): 6,408 @ $0 · Grant/award (A): 19,226 (derivative) @ $0 · Grant/award (A): 19,226 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Schuth Alexander O. — COFO and Secretary | Sale (S): 17,218 @ $16.50 | EDGAR |
| 2026-01-08 | 4 | Watts Ryan J. — President and CEO, Director | Sale (S): 35,198 @ $16.50 | EDGAR |
| 2026-01-05 | 4 | Schuth Alexander O. — COFO and Secretary | Grant/award (A): 57,700 @ $0 · Grant/award (A): 173,100 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Watts Ryan J. — President and CEO, Director | Grant/award (A): 78,960 @ $0 · Grant/award (A): 236,880 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Purchase (P): 190,523 (derivative) @ $17.49 · Purchase (P): 2,095,191 (derivative) @ $17.49 | EDGAR |
| 2025-11-06 | 4 | Van Hauwermeiren Timothy — Director | Grant/award (A): 10,632 @ $0 · Grant/award (A): 31,897 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Watts Ryan J. — President and CEO, Director | Gift (G): 50,000 @ $0 | EDGAR |
| 2025-08-14 | 4 | Schuth Alexander O. — COFO and Secretary | Sale (S): 2,937 @ $13.58 | EDGAR |
| 2025-08-14 | 4 | Ho Carole — Chief Medical Officer | Sale (S): 2,937 @ $13.58 · Sale (S): 806 @ $14.64 | EDGAR |
| 2025-08-07 | 4 | Ho Carole — Chief Medical Officer | Option exercise (M): 44,655 @ $0.68 · Option exercise (M): 44,655 (derivative) @ $0 | EDGAR |
| 2025-07-11 | 4 | Watts Ryan J. — President and CEO, Director | Option exercise (M): 455,282 @ $0.68 · Option exercise (M): 40,000 @ $5.28 · Sale (S): 495,282 @ $15 · Option exercise (M): 455,282 (derivative) @ $0 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Cook Jennifer E. — Director | Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Thornberry Nancy — Director | Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Krognes Steve E. — Director | Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Schenkein David P — Director | Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Klein Peter S — Director | Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Tessier-Lavigne Marc — Director | Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | FLATLEY JAY T — Director | Grant/award (A): 6,037 @ $0 · Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 10,565 @ $0 · Grant/award (A): 10,565 @ $0 · Grant/award (A): 31,695 (derivative) @ $0 · Grant/award (A): 31,695 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Ho Carole — Chief Medical Officer | Sale (S): 12,255 @ $20.22 · Sale (S): 2,907 @ $20.81 | EDGAR |
| 2025-01-08 | 4 | Schuth Alexander O. — COFO and Secretary | Sale (S): 12,255 @ $20.22 · Sale (S): 2,907 @ $20.81 | EDGAR |
| 2025-01-08 | 4 | Watts Ryan J. — President and CEO, Director | Sale (S): 29,266 @ $20.22 · Sale (S): 7,650 @ $20.81 | EDGAR |
| 2025-01-08 | 4 | Krognes Steve E. — Director | Sale (S): 3,339 @ $20.81 | EDGAR |
| 2025-01-07 | 4 | Watts Ryan J. — President and CEO, Director | Grant/award (A): 54,180 @ $0 · Grant/award (A): 162,540 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Schuth Alexander O. — COFO and Secretary | Grant/award (A): 54,180 @ $0 · Grant/award (A): 162,540 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Ho Carole — Chief Medical Officer | Grant/award (A): 54,180 @ $0 · Grant/award (A): 162,540 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Krognes Steve E. — Director | Sale (S): 30,000 @ $20.25 | EDGAR |
| 2025-01-03 | 4 | SATO VICKI L — Director | Sale (S): 3,080 @ $20.91 | EDGAR |
| 2024-12-31 | 4 | Schuth Alexander O. — COFO and Secretary | Option exercise (M): 6,708 @ $5.28 · Option exercise (M): 6,708 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | Ho Carole — Chief Medical Officer | Option exercise (M): 17,845 @ $0.68 · Option exercise (M): 17,845 (derivative) @ $0 | EDGAR |
| 2024-11-26 | 4 | Schuth Alexander O. — COFO and Secretary | Option exercise (M): 20,516 @ $0.68 · Option exercise (M): 20,516 (derivative) @ $0 | EDGAR |
| 2024-11-13 | 4 | Schenkein David P — Director | Option exercise (M): 47,165 @ $18 · Sale (S): 27,129 @ $32.09 · Sale (S): 32,312 @ $32.87 · Option exercise (M): 47,165 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Schuth Alexander O. — COFO and Secretary | Option exercise (M): 15,558 @ $5.28 · Sale (S): 12,333 @ $29.68 · Sale (S): 2,925 @ $30.72 · Sale (S): 300 @ $31.29 · Option exercise (M): 15,558 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | SATO VICKI L — Director | Sale (S): 1,020 @ $30 | EDGAR |
| 2024-11-05 | 4 | SATO VICKI L — Director | Sale (S): 3,080 @ $27.07 | EDGAR |
| 2024-10-22 | 4 | Watts Ryan J. — President and CEO, Director | Option exercise (M): 40,000 @ $0.68 · Sale (S): 40,000 @ $27.69 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Krognes Steve E. — Director | Sale (S): 30,000 @ $29.03 | EDGAR |
Recent 8-K events — Denali Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-28 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-22 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-03 | 8-K | 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-03-25 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DNLI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →